Mountzios et al. found higher concentrations of sRANKL and OPG, as well as a higher sRANKL/OPG ratio, in 30 breast cancer patients with at least one recently diagnosed osteolytic or osteoblastic bone lesion compared to 22 healthy controls [32]. This evidence concerns the gene TNFRSF11B and breast carcinoma.